

October 23, 2014

Company name: Terumo Corporation
Representative: Yutaro Shintaku,
President and Representative Director
Code No.: 4543, TSE Section 1
Inquiries: Masayuki Maruta,
General Manager,
Corporate Communication Dept.
Telephone: +81-3-6742-8550

Terumo transforms product portfolio of Hospital and Laboratory Business in Europe

Terumo will transform product portfolio of Hospital and Laboratory business in Europe towards sustainable and profitable growth. Accordingly, Belgium based Terumo Europe today has informed its Works Council after the board meeting of Terumo Europe held on October 23rd of its intention in that regard.

Hospital and Laboratory business in Europe is experiencing significantly changing market dynamics such as health care reforms, price pressure, and increased production costs. To adapt to these new market dynamics, Terumo decided to revise its strategy; Terumo Europe intends to transition its activities of production and sales of Hospital and Laboratory business (main products: syringe and blood collecting tube for hospital use). If the intended plan would be implemented, up to 260 employees could be impacted in Europe by March 2016.

On another front, the company will continue to focus on and invest in further development of value added activities in the Drug & Device (business-to-business with pharmaceutical companies) and Interventional Systems businesses.

The impact on Terumo's financial results will be disclosed as and when determined.

About Terumo Europe (as of the end of September, 2014)

Name: Terumo Europe N.V.

Established: May 1971

Personnel: 1,200 (including the subsidiaries)

Business: Manufacturing and selling medical devices

-End-